Merge Healthcare buys Confirma
This article was originally published in The Gray Sheet
Executive Summary
Health IT provider Merge Healthcare enters the computer-aided detection (CAD) market through its $22 million stock-swap acquisition of Confirma. Under a definitive agreement announced Aug. 6, Merge gains privately-held Confirma's flagship CADstream system, which combines magnetic resonance imaging technology with CAD to detect breast and prostate cancers. CAD technology "is still at an early adoption phase in the market for most indications, but it has significant opportunity as a tool for reducing imaging costs in today's health care reform environment," Merge Healthcare CEO Justin Dearborn explains. Confirma investors will own about 8.5% of Merge after the deal closes in September
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.